Know Cancer

forgot password

Vaccine Biotherapy of Cancer: Tumor Cells and Dendritic Cells as Active Specific Immunotherapy of Patients With Metastatic Melanoma

Phase 1/Phase 2
16 Years
Not Enrolling
Melanoma (Skin)

Thank you

Trial Information

Vaccine Biotherapy of Cancer: Tumor Cells and Dendritic Cells as Active Specific Immunotherapy of Patients With Metastatic Melanoma


- Determine the safety of immunization with autologous in vitro-treated tumor cells and
dendritic cells in combination with sargramostim (GM-CSF) in patients with stage IV or
recurrent melanoma.

- Determine the frequency of conversion of delayed tumor hypersensitivity tests in
patients treated with this regimen.

- Determine the progression-free and overall survival in patients treated with this

- Determine the objective tumor response rate in patients with measurable melanoma
treated with this regimen.

OUTLINE: Patients are stratified according to presence of measurable disease at study
initiation (yes vs no).

Patients undergo tumor cell harvest. Patients with multiple persistent sites of metastatic
disease after harvest may receive systemic therapy (biologic therapy and/or chemotherapy)
during tumor cell line expansion over approximately 4 months. The tumor cell line is
expanded, irradiated, and treated with interferon gamma.

Patients undergo leukapheresis to collect peripheral blood mononuclear cells (PBMC) to
obtain dendritic cells (DC). The PBMC are treated with sargramostim (GM-CSF) and
interleukin-4 for 7 days to produce DC. The DC are then cultured with the treated tumor
cells for 18 hours.

Patients undergo delayed tumor hypersensitivity tests intradermally 1 week prior to
vaccination and again at week 4. Patients receive vaccine therapy comprising autologous
treated tumor cells and dendritic cells suspended in GM-CSF subcutaneously weekly for 3
weeks. Vaccine therapy continues monthly for an additional 5 months in the absence of
disease progression or unacceptable toxicity.

Patients are followed every 2 months for 1 year and then every 3 months for 4 years.

PROJECTED ACCRUAL: A total of 30-80 patients will be accrued for this study.

Inclusion Criteria


- Histologically confirmed stage IV or recurrent melanoma

- Metastatic disease confirmed by MRI or CT scan

- Planned resection of tumor

- No active CNS metastases

- Radiographically confirmed lack of CNS disease progression

- No requirement for pharmacologic doses of corticosteroids



- Over 16

Performance status:

- ECOG 0-2

Life expectancy:

- At least 4 months


- Hematocrit greater than 25%

- Platelet count greater than 100,000/mm^3

- No ongoing transfusion requirements

- No active blood clotting or bleeding diathesis


- Bilirubin no greater than 2.0 mg/dL

- Albumin at least 3.0 g/dL


- Creatinine no greater than 2.0 mg/dL


- No underlying cardiac disease associated with known myocardial dysfunction

- No unstable angina related to atherosclerotic cardiovascular disease


- No other malignancy within the past 5 years except for carcinoma in situ, basal cell
carcinoma, or localized squamous cell skin cancer

- No active, eminently life-threatening infection or medical condition

- Adequate venous access

- Not pregnant

- Fertile patients must use effective contraception


Biologic therapy:

- Other prior putative vaccines allowed

- Recovered from prior biologic therapy

- No other concurrent biologic therapy except epoetin alfa for patients with hematocrit
less than 36%


- At least 3 weeks since prior chemotherapy and recovered

- No concurrent chemotherapy

Endocrine therapy:

- See Disease Characteristics

- No concurrent endocrine therapy


- At least 3 weeks since prior radiotherapy (including whole brain radiotherapy) and

- No concurrent radiotherapy


- See Disease Characteristics

- Recovered from prior surgery


- Concurrent bisphosphonates allowed for patients with lytic bone metastases

- No concurrent digoxin or other medications designed to improve cardiac output

- No other concurrent investigational therapy

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the safety of administration of irradiated autologous tumor cells that have been incubated in vitro with gamma interferon, and subsequently injected subcutaneously with autologous dendritic cells and GMCSF

Outcome Time Frame:


Safety Issue:


Principal Investigator

Robert O. Dillman, MD, FACP

Investigator Role:

Study Chair

Investigator Affiliation:

Hoag Memorial Hospital Presbyterian


United States: Food and Drug Administration

Study ID:




Start Date:

July 2000

Completion Date:

April 2011

Related Keywords:

  • Melanoma (Skin)
  • stage IV melanoma
  • recurrent melanoma
  • Melanoma



Hoag Cancer Center at Hoag Memorial Hospital Presbyterian Newport Beach, California  92663